e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Jan-Willem C. Alffenaar, Onno W. Akkerman, Simon Tiberi, Giovanni Sotgiu, Giovanni Battista Migliori
Source:
Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jan-Willem C. Alffenaar, Onno W. Akkerman, Simon Tiberi, Giovanni Sotgiu, Giovanni Battista Migliori. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 564-574
Year: 2016
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis
Source: Annual Congress 2009 - Priorities in tuberculosis research
Year: 2009
Multidrug- and extensively drug-resistant tuberculosis: an emerging threat
Source: Eur Respir Rev 2009; 18: 195-197
Year: 2009
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017
Year: 2017
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city
Source: Eur Respir J 2013; 41: 901-908
Year: 2013
Risk factors for treatment failure in multidrug-resistant and extensively drug-resistant tuberculosis in Estonia
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen
Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018
Year: 2018
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
Source: Eur Respir J 2016; 48: 935-938
Year: 2016
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Source: Eur Respir J 2007; 30: 623-626
Year: 2007
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept